Drug Type Antibody |
Synonyms Non alpha IL-2, Non alpha synthorin of IL-2, IBI-127 + [2] |
Target |
Mechanism IL-2R agonists(Interleukin-2 receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |
Start Date24 Aug 2022 |
Sponsor / Collaborator |
Start Date07 Jul 2022 |
Sponsor / Collaborator |
Start Date09 Dec 2021 |
Sponsor / Collaborator [+1] |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Human Papillomavirus-Related Oropharyngeal Neoplasms | Phase 2 | US | 24 Aug 2022 | |
Squamous Cell Carcinoma | Phase 2 | US | 24 Aug 2022 | |
Squamous Cell Carcinoma of the Oropharynx | Phase 2 | US | 24 Aug 2022 | |
Neoplasms | Phase 2 | US | 30 Jan 2022 | |
Adenocarcinoma of Esophagus | Phase 2 | US | 09 Dec 2021 | |
Adenocarcinoma of Esophagus | Phase 2 | CN | 09 Dec 2021 | |
Adenocarcinoma of Esophagus | Phase 2 | BE | 09 Dec 2021 | |
Adenocarcinoma of Esophagus | Phase 2 | CL | 09 Dec 2021 | |
Adenocarcinoma of Esophagus | Phase 2 | FR | 09 Dec 2021 | |
Adenocarcinoma of Esophagus | Phase 2 | IT | 09 Dec 2021 |
Study | Phase | Population | Analyzed Enrollment | Group | Results | Evaluation | Publication Date |
---|
Phase 1 | 116 | (Arm A) | obmxiedyso(pnqsxfkqmo) = 24 μg/kg kekxywjnlj (hpatintnry ) View more | Positive | 10 Sep 2022 | ||
(Arm B) | |||||||
Phase 1/2 | Solid tumor Second line | 28 | THOR-707 (8 µg/kg (n=4)) | ccdxklnmcw(ikfnzfhrnz) = sgivqriuno zivhmulyzs (ehysdhbdza ) View more | Positive | 10 Apr 2021 | |
THOR-707 (8 µg/kg (n=4), 16 µg/kg (n=6), 24 µg/kg (n=7)) | ccdxklnmcw(ikfnzfhrnz) = chkbicljwf zivhmulyzs (ehysdhbdza ) View more |